Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

JCR Pharmaceuticals Co stock price, quote, forecast and news

4552.T
JP3701000006
889627

Price

660.00
Today +/-
-0.02
Today %
-0.45 %
P

JCR Pharmaceuticals Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the JCR Pharmaceuticals Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the JCR Pharmaceuticals Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the JCR Pharmaceuticals Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze JCR Pharmaceuticals Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

JCR Pharmaceuticals Co Stock Price History

DateJCR Pharmaceuticals Co Price
9/13/2024660.00 undefined
9/12/2024663.00 undefined
9/11/2024630.00 undefined
9/10/2024644.00 undefined
9/9/2024652.00 undefined
9/6/2024665.00 undefined
9/5/2024634.00 undefined
9/4/2024628.00 undefined
9/3/2024654.00 undefined
9/2/2024612.00 undefined
8/30/2024626.00 undefined
8/29/2024614.00 undefined
8/28/2024620.00 undefined
8/27/2024630.00 undefined
8/26/2024616.00 undefined
8/23/2024616.00 undefined
8/22/2024622.00 undefined
8/21/2024607.00 undefined
8/20/2024604.00 undefined
8/19/2024574.00 undefined

JCR Pharmaceuticals Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into JCR Pharmaceuticals Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by JCR Pharmaceuticals Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects JCR Pharmaceuticals Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of JCR Pharmaceuticals Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into JCR Pharmaceuticals Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing JCR Pharmaceuticals Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on JCR Pharmaceuticals Co’s growth potential.

JCR Pharmaceuticals Co Revenue, EBIT and net profit per share

DateJCR Pharmaceuticals Co RevenueJCR Pharmaceuticals Co EBITJCR Pharmaceuticals Co Net Income
2027e42.15 B undefined0 undefined5.33 B undefined
2026e41.65 B undefined0 undefined4.59 B undefined
2025e41.9 B undefined0 undefined4.82 B undefined
202442.87 B undefined7.53 B undefined5.51 B undefined
202334.34 B undefined4.98 B undefined3.77 B undefined
202251.08 B undefined19.93 B undefined14.51 B undefined
202130.09 B undefined8.27 B undefined6.89 B undefined
202024.78 B undefined3.24 B undefined2.68 B undefined
201923.16 B undefined4.97 B undefined3.72 B undefined
201820.59 B undefined3.78 B undefined3.07 B undefined
201718.09 B undefined2.36 B undefined1.86 B undefined
201617.44 B undefined2.15 B undefined1.79 B undefined
201516.86 B undefined2.01 B undefined1.68 B undefined
201415.71 B undefined1.55 B undefined1.3 B undefined
201314.1 B undefined1.15 B undefined731 M undefined
201212.85 B undefined1.09 B undefined634 M undefined
201114.46 B undefined1.41 B undefined926 M undefined
201014.39 B undefined2.01 B undefined1.3 B undefined
200912.08 B undefined546 M undefined540 M undefined
200811.87 B undefined212 M undefined400 M undefined
20078.55 B undefined-406 M undefined-1.75 B undefined
20067.65 B undefined-296 M undefined-42 M undefined
20058.1 B undefined459 M undefined-1.28 B undefined

JCR Pharmaceuticals Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
10.199.137.268.588.117.587.488.17.658.5511.8712.0814.3914.4612.8514.115.7116.8617.4418.0920.5923.1624.7830.0951.0834.3442.8741.941.6542.15
--10.45-20.4618.17-5.40-6.57-1.378.33-5.5711.7138.941.7819.070.49-11.169.7711.397.323.463.7113.8712.467.0021.4069.79-32.7724.83-2.26-0.611.22
42.5043.9038.5635.0044.9343.2946.6054.8958.9264.1867.1970.5771.2163.8467.2064.2853.2659.8961.0266.2368.5070.2768.1274.0379.5274.1372.90---
4.334.012.833.653.283.484.454.515.487.988.5310.259.238.639.068.3710.0910.6411.9814.1116.2816.8822.2740.6225.4631.25000
1.431.30.180.20.530.270.390.46-0.3-0.410.210.552.011.411.091.151.552.012.152.363.784.973.248.2719.934.987.53000
14.0614.252.522.326.493.555.205.67-3.87-4.751.794.5213.969.738.498.169.8411.9512.3413.0618.3721.4513.0927.4939.0214.4917.57---
0.80.590.050.290.130.080.01-1.28-0.04-1.750.40.541.30.930.630.731.31.681.791.863.073.722.686.8914.513.775.514.824.595.33
--26.18-90.88433.33-54.86-41.54-86.84-12,940.00-96.734,069.05-122.8435.00141.30-28.93-31.5315.3077.2929.786.364.1464.7921.01-27.91157.36110.49-74.0046.00-12.51-4.8216.11
------------------------------
------------------------------
181921222020202021272727293232323232.03128.27127.16125.17123.88124.04124.13124.21124.84125.4000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The JCR Pharmaceuticals Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the JCR Pharmaceuticals Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
4.256.372.72.793.492.812.153.353.136.046.997.46.944.424.074.697.244.873.885.816.118.511.1926.2630.9813.2818.76
4.734.264.573.954.483.493.313.153.023.032.9133.043.94.044.93.875.25.385.437.18.847.988.1815.5911.1414.93
1.21.110.571.030.160.240.4100000000000000000000
3.765.275.496.586.996.686.134.613.953.673.343.224.14.585.114.995.116.47.347.749.029.128.8613.5514.6418.5120.93
0.150.360.650.810.330.430.491.51.550.511.370.620.880.931.021.41.150.711.761.330.590.920.320.550.994.872.96
14.0917.3613.9715.1615.4413.6412.4812.611.6513.2514.614.2414.9513.8214.2415.9917.3717.1918.3720.3222.8327.3728.3448.5562.1947.857.58
6.216.588.27.897.467.016.667.146.836.676.727.448.9110.329.7410.3711.3911.6111.4411.3910.8511.0614.8817.1726.7832.6830.04
1.191.151.371.250.90.811.171.051.613.171.722.54.524.413.253.533.33.894.253.593.192.942.412.572.238.879.12
5135333317217217200000000000000000000
0.010.010.020.010.020.020.020.020.020.020.020.060.120.120.10.080.10.080.080.070.110.110.263.232.963.653.5
000000000000000000000000000
0.780.961.110.921.61.41.720.990.691.31.150.540.641.151.641.321.311.321.21.031.411.041.892.262.971.941.99
8.248.7210.7410.1110.159.419.759.29.1511.159.6110.5314.21614.7215.316.0916.916.9816.0715.5715.1519.4325.2434.9547.1444.65
22.3326.0824.725.2625.5923.0522.2321.820.824.424.2224.7729.1529.8228.9731.2933.4634.0935.3536.3938.442.5247.7873.7897.1394.94102.23
                                                     
3.884.374.924.925.175.175.175.175.567.517.517.518.069.069.069.069.069.069.069.069.069.069.069.069.069.069.06
4.655.145.685.685.945.945.945.946.468.418.418.419.7810.7810.7810.7910.9310.9510.9610.9610.9510.9210.8910.9410.9910.3810.38
6.146.56.236.216.015.845.613.393.111.081.21.572.553.033.313.694.615.947.178.4310.8113.7915.6221.4233.8135.0138.09
00000007484103454470-15249558147.6560.2846.651028197-462127865
0005742-24466337025514-381115445405568732.89587.93569.64462773583691619555741
14.681616.8316.8617.1616.9216.7614.6415.5817.3517.1817.520.5722.9223.2224.0425.2326.8427.8429.0731.3934.6236.2642.0754.4855.1459.14
0.810.910.332.071.110.980.820.380.330.350.440.810.920.960.230.740.70.530.780.70.590.590.682.931.321.560.89
0.320.220.160.20.250.270.240.170.180.20.210.240.30.310.330.390.430.460.560.60.640.740.790.9111.091.13
1.140.880.520.660.60.390.30.50.471.221.541.562.151.541.622.222.431.982.741.682.793.554.0412.3224.5615.7719.12
0.270.760.290.190.090.0100000000001.211.211.211.262.482.783.7812.112.115.18.2
1.021.820.882.893.462.33.162.912.42.281.881.891.992.032.242.280.890.950.780.460.611.031.150.773.072.240.8
3.574.582.1865.513.934.533.973.394.044.064.495.364.834.425.635.665.136.074.717.118.6810.4329.0342.0535.7630.14
4.025.415.652.312.932.381.143.541.842.93.23.193.162.071.81.872.161.481.213.122.721.923.835.292.995.5714.43
0002000000000000000000000000
0.070.090.050.060.090.130.20.070.090.210.10.10.140.090.110.291.061.211.010.981.051.040.930.9111.191.18
4.095.55.692.43.022.51.353.61.933.113.33.293.32.151.912.163.222.692.224.093.772.964.766.23.996.7615.62
7.6610.087.878.48.536.445.887.575.327.157.377.788.666.996.337.798.887.828.288.810.8711.6415.235.2346.0542.5245.75
22.3326.0824.725.2625.6923.3622.6422.2120.924.524.5525.2829.2329.929.5531.8334.1134.6636.1337.8742.2646.2651.4577.3100.5397.66104.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of JCR Pharmaceuticals Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand JCR Pharmaceuticals Co's financial health and stability.

Assets

JCR Pharmaceuticals Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that JCR Pharmaceuticals Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of JCR Pharmaceuticals Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into JCR Pharmaceuticals Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.190.480.280.210.11-1.930.04-0.610.440.561.581.270.941.061.682.332.462.493.94.933.428.6519.45.41
0.350.520.770.670.550.550.620.590.580.690.740.981.10.981.111.351.411.451.381.341.431.891.952
000000000000000000000000
-1.640.97-1.680.30.431.920.41.060.790.51-0.51-2.4-2.59-0.551.21-3.03-0.69-2.06-2.23-2.490.02-0.25-11.75-12.18
919530356915998-3119812458540133125169569-159-974775841275747-306-733
938257665952525965626958575043373228272122464546
0.750.10.450.180.14-0.010.010.040.010.010.030.790.510.280.490.790.211.130.131.271.260.812.528.28
-1.012.06-0.321.751.250.640.751.131.921.832.36-0.02-0.421.664.570.52.22.653.133.914.9310.349.29-5.5
-2,248-502-220-53-100-976-166-175-745-523-1,922-1,152-292-1,048-2,409-1,340-1,413-1,550-999-895-4,838-7,527-11,333-8,560
-0.98-0.33-0.1-0.31-1.12-1.230.13-4.63-0.570.12-3.4-2.211.54-0.18-2.67-1.42-0.98-0.84-1.590.24-4.16-3.29-3.25-15
1.270.170.12-0.26-1.02-0.260.3-4.460.170.65-1.47-1.061.830.87-0.26-0.080.430.71-0.591.140.684.248.08-6.44
000000000000000000000000
0.39-1.291.76-1.71-0.371.77-10.92-0.11-0.83-0.19-0.79-0.160.10.02-0.71-0.471.590.98-0.113.029.37-0.024.68
-0-0.07-0.03-0.21-0.1100.013.88-0.23-0.182.260-0.520.040.030.04-0.21-0.74-2.590.030.020.010.010.01
0.1-1.661.43-2.17-0.711.68-1.114.53-0.51-1.281.76-1.28-1.07-0.24-0.37-1.26-1.310.15-2.18-0.922.058.3-2.181.95
000001381280950-5200000001830-210-1
-292-299-301-245-236-234-242-268-273-270-253-485-385-382-412-592-640-699-748-834-989-1,083-2,169-2,739
-1.920.121.01-0.72-0.61.09-0.211.040.820.640.71-3.520.051.281.63-2.14-0.121.94-0.613.242.8415.334.47-17.45
-3,255.31,560.9-5431,697.21,149.6-334.6580.3954.31,177.91,302.4434.9-1,170.5-713.2613.42,155.8-841.23787.811,100.742,1353,011912,813-2,044-14,059
000000000000000000000000

JCR Pharmaceuticals Co stock margins

The JCR Pharmaceuticals Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of JCR Pharmaceuticals Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for JCR Pharmaceuticals Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the JCR Pharmaceuticals Co's sales revenue. A higher gross margin percentage indicates that the JCR Pharmaceuticals Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the JCR Pharmaceuticals Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the JCR Pharmaceuticals Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the JCR Pharmaceuticals Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the JCR Pharmaceuticals Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the JCR Pharmaceuticals Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

JCR Pharmaceuticals Co Margin History

JCR Pharmaceuticals Co Gross marginJCR Pharmaceuticals Co Profit marginJCR Pharmaceuticals Co EBIT marginJCR Pharmaceuticals Co Profit margin
2027e72.9 %0 %12.63 %
2026e72.9 %0 %11.01 %
2025e72.9 %0 %11.5 %
202472.9 %17.57 %12.85 %
202374.13 %14.49 %10.98 %
202279.52 %39.02 %28.4 %
202174.03 %27.49 %22.91 %
202068.12 %13.09 %10.81 %
201970.27 %21.45 %16.04 %
201868.5 %18.37 %14.91 %
201766.24 %13.06 %10.3 %
201661.03 %12.35 %10.26 %
201559.89 %11.95 %9.98 %
201453.26 %9.84 %8.25 %
201364.28 %8.16 %5.18 %
201267.2 %8.49 %4.94 %
201163.84 %9.73 %6.4 %
201071.21 %13.96 %9.06 %
200970.57 %4.52 %4.47 %
200867.19 %1.79 %3.37 %
200764.18 %-4.75 %-20.49 %
200658.92 %-3.87 %-0.55 %
200554.89 %5.67 %-15.85 %

JCR Pharmaceuticals Co Stock Sales Revenue, EBIT, Earnings per Share

The JCR Pharmaceuticals Co earnings per share therefore indicates how much revenue JCR Pharmaceuticals Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue JCR Pharmaceuticals Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates JCR Pharmaceuticals Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of JCR Pharmaceuticals Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating JCR Pharmaceuticals Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

JCR Pharmaceuticals Co Revenue, EBIT and net profit per share

DateJCR Pharmaceuticals Co Sales per ShareJCR Pharmaceuticals Co EBIT per shareJCR Pharmaceuticals Co Earnings per Share
2027e337.7 undefined0 undefined42.67 undefined
2026e333.63 undefined0 undefined36.74 undefined
2025e335.67 undefined0 undefined38.61 undefined
2024341.88 undefined60.06 undefined43.92 undefined
2023275.1 undefined39.85 undefined30.22 undefined
2022411.26 undefined160.48 undefined116.79 undefined
2021242.36 undefined66.61 undefined55.52 undefined
2020199.78 undefined26.15 undefined21.59 undefined
2019186.96 undefined40.1 undefined29.99 undefined
2018164.53 undefined30.23 undefined24.53 undefined
2017142.22 undefined18.58 undefined14.65 undefined
2016135.95 undefined16.78 undefined13.95 undefined
2015526.28 undefined62.9 undefined52.53 undefined
2014490.81 undefined48.31 undefined40.5 undefined
2013440.63 undefined35.97 undefined22.84 undefined
2012401.41 undefined34.06 undefined19.81 undefined
2011451.81 undefined43.97 undefined28.94 undefined
2010496.1 undefined69.24 undefined44.93 undefined
2009447.52 undefined20.22 undefined20 undefined
2008439.7 undefined7.85 undefined14.81 undefined
2007316.48 undefined-15.04 undefined-64.85 undefined
2006364.24 undefined-14.1 undefined-2 undefined
2005405 undefined22.95 undefined-64.2 undefined

JCR Pharmaceuticals Co business model

JCR Pharmaceuticals Co. Ltd is a Japanese company founded in 1975. It is a global provider of biopharmaceutical products and services and is based in Ashiya, Japan. The company specializes in researching and developing therapies for rare genetic diseases, including the production of recombinant proteins and antibodies. It has three main business areas: biopharmaceuticals, diagnostics, and research services. JCR Pharmaceuticals works closely with universities, research institutions, and other companies to advance biotechnology research. It follows an ethical business model focused on integrity, transparency, openness, and fairness. The company has expanded into Europe and invested in a new research and development facility to enhance its presence and improve access to novel therapies for patients. Overall, JCR Pharmaceuticals has a strong position in the biotechnology and rare diseases field and has the potential to positively impact the lives of millions of people worldwide. JCR Pharmaceuticals Co is one of the most popular companies on Eulerpool.com.

JCR Pharmaceuticals Co SWOT Analysis

Strengths

  • Strong market presence within the pharmaceutical industry.
  • Extensive research and development capabilities, leading to innovative products.
  • Robust manufacturing facilities ensuring high-quality production.
  • Well-established distribution network, enabling wide market reach.

Weaknesses

  • Dependence on a limited number of key products, making the company vulnerable to shifts in market demand.
  • Relatively small size compared to global pharmaceutical giants, which may limit resources and influence.
  • Limited international presence, potentially hindering expansion into new markets.

Opportunities

  • Growing demand for pharmaceutical products due to an aging global population.
  • Increasing focus on personalized medicine, aligning with JCR Pharmaceuticals' expertise in biotechnology.
  • Potential partnerships with global pharmaceutical companies for joint research and product development.
  • Expanding into emerging markets with unmet medical needs.

Threats

  • Intense competition within the pharmaceutical industry, including both established companies and emerging startups.
  • Stringent regulations and compliance requirements, particularly in international markets.
  • Rapid advancements in technology and science, necessitating continuous innovation to stay competitive.
  • Potential negative impact from economic fluctuations and healthcare policies.

JCR Pharmaceuticals Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

JCR Pharmaceuticals Co historical P/E ratio, EBIT, and P/S ratio.

JCR Pharmaceuticals Co shares outstanding

The number of shares was JCR Pharmaceuticals Co in 2023 — This indicates how many shares 124.838 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue JCR Pharmaceuticals Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates JCR Pharmaceuticals Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of JCR Pharmaceuticals Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating JCR Pharmaceuticals Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

JCR Pharmaceuticals Co Stock splits

In JCR Pharmaceuticals Co's history, there have been no stock splits.

JCR Pharmaceuticals Co dividend history and estimates

In 2023, JCR Pharmaceuticals Co paid a dividend amounting to 20 JPY. Dividend means that JCR Pharmaceuticals Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for JCR Pharmaceuticals Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify JCR Pharmaceuticals Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating JCR Pharmaceuticals Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

JCR Pharmaceuticals Co Dividend History

DateJCR Pharmaceuticals Co Dividend
2027e24.68 undefined
2026e24.61 undefined
2025e24.73 undefined
202420 undefined
202320 undefined
202212 undefined
202110.5 undefined
20208.75 undefined
20198 undefined
20186.75 undefined
20176 undefined
20163 undefined
20155 undefined
20143.88 undefined
20133.25 undefined
20123 undefined
20113 undefined
20102.75 undefined
20092.5 undefined
20082.5 undefined
20072.5 undefined
20062.75 undefined
20053 undefined

JCR Pharmaceuticals Co dividend payout ratio

In 2023, JCR Pharmaceuticals Co had a payout ratio of 23.24%. The payout ratio indicates the percentage of the company's profits that JCR Pharmaceuticals Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for JCR Pharmaceuticals Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for JCR Pharmaceuticals Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate JCR Pharmaceuticals Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

JCR Pharmaceuticals Co Payout Ratio History

DateJCR Pharmaceuticals Co Payout ratio
2027e17.9 %
2026e19.24 %
2025e17 %
202417.47 %
202323.24 %
202210.27 %
202118.91 %
202040.53 %
201926.68 %
201827.52 %
201740.95 %
201621.5 %
20159.52 %
20149.57 %
201314.23 %
201215.14 %
201110.37 %
20106.12 %
200912.5 %
200816.88 %
2007-3.86 %
2006-137.5 %
2005-4.67 %
Unfortunately, there are currently no price targets and forecasts available for JCR Pharmaceuticals Co.

JCR Pharmaceuticals Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20248.58 1.61  (-81.24 %)2025 Q1
3/31/202416.86 2.78  (-83.51 %)2024 Q4
12/31/202311.49 -0.75  (-106.52 %)2024 Q3
9/30/202313.08 29.19  (123.19 %)2024 Q2
6/30/20237.64 12.91  (69.05 %)2024 Q1
3/31/20236.87 1.64  (-76.17 %)2023 Q4
12/31/20220.59 20.96  (3,478.01 %)2023 Q3
9/30/20220.1 -3.29  (-3,263.46 %)2023 Q2
6/30/2022-1.25 11.06  (981.7 %)2023 Q1
3/31/202237.13 12.82  (-65.48 %)2022 Q4
1
2

JCR Pharmaceuticals Co list of shareholders

%
Name
Stocks
Change
Date
7.76810 % Nomura Asset Management Co., Ltd.9,696,5001,785,7002/29/2024
6.97859 % Future Brain KK8,711,00009/30/2023
6.20711 % Nomura Trust & Banking (Trust)7,748,0001,240,0009/30/2023
3.93993 % Kissei Pharmaceutical Co Ltd4,918,000-1,500,0009/30/2023
23.33755 % Medipal Holdings Corp29,131,000-2929/30/2023
2.72382 % Sumitomo Pharma Co Ltd3,400,00009/30/2023
2.26051 % Norges Bank Investment Management (NBIM)2,821,6701,228,67012/31/2023
1.76247 % Mochida Pharmaceutical Co Ltd2,200,00009/30/2023
1.25601 % The Vanguard Group, Inc.1,567,804-1,8163/31/2024
0.90815 % BlackRock Institutional Trust Company, N.A.1,133,60010,8003/31/2024
1
2
3
4
5
...
10

JCR Pharmaceuticals Co Executives and Management Board

Dr. Mathias Schmidt55
JCR Pharmaceuticals Co Managing Director, President and Chief Executive Officer of Subsidiaries (since 2020)
Compensation 135 M
Mr. Shin Ashida77
JCR Pharmaceuticals Co Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer, President of Subsidiary, Representative Director (since 1975)
Compensation 108 M
Mr. Toru Ashida54
JCR Pharmaceuticals Co Senior Managing Director, Chief Director of Sales (since 2014)
Mr. Hiroyuki Sonoda45
JCR Pharmaceuticals Co Managing Director, Chief Director of Research (since 2018)
Mr. Yoh Ito
JCR Pharmaceuticals Co Senior Executive Officer, Chief Director of Business Strategy
1
2
3
4

JCR Pharmaceuticals Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
PALTAC Stock
PALTAC
SupplierCustomer0,780,57-0,150,530,870,66
PeptiDream Stock
PeptiDream
SupplierCustomer0,75-0,250,600,640,930,67
Sumitomo Pharma Stock
Sumitomo Pharma
SupplierCustomer0,72-0,19-0,350,600,940,77
Medipal Holdings Stock
Medipal Holdings
SupplierCustomer0,690,44-0,38-0,260,400,40
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,600,230,860,02-0,39-0,42
ASKA Pharmaceutical Stock
ASKA Pharmaceutical
SupplierCustomer0,43-0,360,69-0,03-0,290,06
Kissei Pharmaceutical Stock
Kissei Pharmaceutical
SupplierCustomer0,420,500,42-0,14-0,42-0,09
Teijin Stock
Teijin
SupplierCustomer0,280,28-0,120,080,870,61
ASKA Pharmaceutical Co., Ltd. Stock
ASKA Pharmaceutical Co., Ltd.
SupplierCustomer-0,16-0,54-0,840,33-0,29-
Mesoblast Stock
Mesoblast
SupplierCustomer-0,26-0,42-0,290,730,900,26
1
2

Most common questions regarding JCR Pharmaceuticals Co

What values and corporate philosophy does JCR Pharmaceuticals Co represent?

JCR Pharmaceuticals Co Ltd represents a commitment to innovation, quality, and improving lives through its pharmaceutical products. With a strong corporate philosophy focused on ethical practices and social responsibility, JCR Pharmaceuticals aims at providing cutting-edge medical solutions that contribute to human health and well-being. By continuously investing in research and development, JCR Pharmaceuticals strives to deliver effective and safe medicines to patients worldwide. The company values transparency, sustainability, and collaboration in its pursuit of groundbreaking therapies and advancements in the pharmaceutical industry. JCR Pharmaceuticals Co Ltd is dedicated to improving the quality of life for individuals and communities by prioritizing excellence, integrity, and patient-centricity.

In which countries and regions is JCR Pharmaceuticals Co primarily present?

JCR Pharmaceuticals Co Ltd is primarily present in Japan.

What significant milestones has the company JCR Pharmaceuticals Co achieved?

JCR Pharmaceuticals Co Ltd has achieved significant milestones in its journey. Notably, the company successfully developed and launched its flagship product, JR-031, which has revolutionized the treatment of claudication and other peripheral arterial diseases. JCR Pharmaceuticals Co Ltd further secured regulatory approvals for expanding JR-031's indications, strengthening its market position. Additionally, the company successfully initiated strategic collaborations with renowned organizations to further advance its pipeline and diversify its portfolio. JCR Pharmaceuticals Co Ltd's commitment to innovation and expertise in the pharmaceutical industry has enabled the company to achieve these remarkable milestones.

What is the history and background of the company JCR Pharmaceuticals Co?

JCR Pharmaceuticals Co Ltd is a renowned company in the pharmaceutical industry. Established in 1975, JCR Pharmaceuticals has a rich history of over four decades. The company specializes in the development, manufacturing, and commercialization of innovative biopharmaceuticals and regenerative medicine products. With a strong focus on research and development, JCR Pharmaceuticals strives to provide advanced solutions for various medical conditions. JCR Pharmaceuticals Co Ltd has evolved into a trusted global leader, committed to improving patients' lives through groundbreaking medical advancements.

Who are the main competitors of JCR Pharmaceuticals Co in the market?

The main competitors of JCR Pharmaceuticals Co Ltd in the market include other prominent pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.

In which industries is JCR Pharmaceuticals Co primarily active?

JCR Pharmaceuticals Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of JCR Pharmaceuticals Co?

The business model of JCR Pharmaceuticals Co Ltd focuses on the development and commercialization of innovative therapeutic products. JCR Pharmaceuticals specializes in the research and production of biopharmaceuticals, aiming to contribute to advancements in healthcare. Their diversified portfolio encompasses various therapeutic areas, such as regenerative medicine, oncology, and autoimmune diseases. By leveraging their expertise in biotechnology, JCR Pharmaceuticals strives to deliver effective and safe treatments to patients worldwide. With a commitment to research and development, the company aims to improve the quality of life for individuals with different medical conditions through their innovative therapies.

What is the P/E ratio of JCR Pharmaceuticals Co 2024?

The JCR Pharmaceuticals Co P/E ratio is 15.03.

What is the P/S ratio of JCR Pharmaceuticals Co 2024?

The JCR Pharmaceuticals Co P/S ratio is 1.93.

What is the AlleAktien quality score of JCR Pharmaceuticals Co?

The AlleAktien quality score for JCR Pharmaceuticals Co is 5/10.

What is the revenue of JCR Pharmaceuticals Co 2024?

The JCR Pharmaceuticals Co revenue is 42.87 B JPY.

How high is the profit of JCR Pharmaceuticals Co 2024?

The JCR Pharmaceuticals Co profit is 5.51 B JPY.

What is the business model of JCR Pharmaceuticals Co

JCR Pharmaceuticals is an international Japanese pharmaceutical company specializing in the development, production, and marketing of innovative medical products. The company operates in various divisions including Regenerative Medicine, Oncology, Diagnostics, and Therapeutics. In addition to preserving and improving human health, the company also focuses on the environment and resource conservation.

What is the JCR Pharmaceuticals Co dividend?

JCR Pharmaceuticals Co pays a dividend of 12 JPY distributed over payouts per year.

How often does JCR Pharmaceuticals Co pay dividends?

The dividend cannot currently be calculated for JCR Pharmaceuticals Co or the company does not pay out a dividend.

What is the JCR Pharmaceuticals Co ISIN?

The ISIN of JCR Pharmaceuticals Co is JP3701000006.

What is the JCR Pharmaceuticals Co WKN?

The WKN of JCR Pharmaceuticals Co is 889627.

What is the JCR Pharmaceuticals Co ticker?

The ticker of JCR Pharmaceuticals Co is 4552.T.

How much dividend does JCR Pharmaceuticals Co pay?

Over the past 12 months, JCR Pharmaceuticals Co paid a dividend of 20 JPY . This corresponds to a dividend yield of about 3.03 %. For the coming 12 months, JCR Pharmaceuticals Co is expected to pay a dividend of 24.73 JPY.

What is the dividend yield of JCR Pharmaceuticals Co?

The current dividend yield of JCR Pharmaceuticals Co is 3.03 %.

When does JCR Pharmaceuticals Co pay dividends?

JCR Pharmaceuticals Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of JCR Pharmaceuticals Co?

JCR Pharmaceuticals Co paid dividends every year for the past 23 years.

What is the dividend of JCR Pharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 24.73 JPY are expected. This corresponds to a dividend yield of 3.75 %.

In which sector is JCR Pharmaceuticals Co located?

JCR Pharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von JCR Pharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of JCR Pharmaceuticals Co from 12/1/2024 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did JCR Pharmaceuticals Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of JCR Pharmaceuticals Co in the year 2023?

In the year 2023, JCR Pharmaceuticals Co distributed 20 JPY as dividends.

In which currency does JCR Pharmaceuticals Co pay out the dividend?

The dividends of JCR Pharmaceuticals Co are distributed in JPY.

All fundamentals about JCR Pharmaceuticals Co

Our stock analysis for JCR Pharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of JCR Pharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.